Obeticholic acid (OCA, Ocaliva) is a potent farnesoid x receptor (FXR) agonist approved by the FDA in 2016 as a second line drug for patients with PBC who do not respond adequately to or cannot tolerate UDCA treatment (5, 6, 7, 8). This evidence concerns the gene NR1H4 and primary biliary cholangitis.